Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
National Cancer Institute · Stony Brook University · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
629
total citations
- FWCI
- 20.05
- Percentile
- 100%
- References
- 31
Citations per year
Authors
4- XZXiaolei ZhuCorresponding
National Cancer Institute, Stony Brook University, VA Connecticut Healthcare System, Stony Brook School, Yale University
- SWShenhong Wu
Yale University, VA Connecticut Healthcare System, National Cancer Institute
- WLWilliam L. Dahut
National Cancer Institute, Yale University, VA Connecticut Healthcare System
- CRChirag R. Parikh
VA Connecticut Healthcare System, Yale University, National Cancer Institute
Topics & keywords
Topics
Keywords
- Bevacizumab
- Medicine
- Proteinuria
- Internal medicine
- Oncology
- Relative risk
- Meta-analysis
- Vascular endothelial growth factor
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.